We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $4.28B
1-Year Est. Return 239%
This Fund
S&P 500
This Quarter Est. Return
+17.74%
1 Year Est. Return
+239%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.28B
AUM Growth
+$703M
Cap. Flow
+$110M
Cap. Flow %
2.57%
Top 10 Hldgs %
50.29%
Holding
99
New
9
Increased
31
Reduced
22
Closed
31

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$203M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$134M
3
ABT icon
Abbott
ABT
+$128M
4
ZBH icon
Zimmer Biomet
ZBH
+$106M
5
PODD icon
Insulet
PODD
+$103M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$281M
2
APGE
Apogee Therapeutics
APGE
+$92.6M
3
SRRK icon
Scholar Rock
SRRK
+$65.1M
4
RGEN icon
Repligen
RGEN
+$64.5M
5
VERA icon
Vera Therapeutics
VERA
+$55M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
1
BioMarin Pharmaceuticals
BMRN
$12.7B
$345M 8.06%
6,025,000
+2,450,000
+69% +$134M
NBIX icon
2
Neurocrine Biosciences
NBIX
$16B
$317M 7.4%
1,880,000
+630,000
+50% +$93.5M
ABVX
3
Abivax
ABVX
$10.3B
$313M 7.32%
2,349,443
+849,443
+57% +$96.1M
UTHR icon
4
United Therapeutics
UTHR
$21.4B
$236M 5.51%
435,000
+360,000
+480% +$203M
ELVN icon
5
Enliven Therapeutics
ELVN
$4B
$203M 4.74%
4,000,000
+750,000
+23% +$31.8M
NRIX icon
6
Nurix Therapeutics
NRIX
$2.62B
$195M 4.56%
8,050,000
+1,550,000
+24% +$26.4M
BCAX
7
Bicara Therapeutics
BCAX
$1.52B
$156M 3.64%
5,250,000
-175,000
-3% -$3.91M
TSHA icon
8
Taysha Gene Therapies
TSHA
$1.64B
$132M 3.09%
19,415,000
+1,415,000
+8% +$8.37M
ARWR icon
9
Arrowhead Research
ARWR
$11.7B
$128M 3%
1,575,000
-700,000
-31% -$51.7M
ABT icon
10
Abbott
ABT
$177B
$127M 2.97%
+1,400,000
New +$128M
ZBH icon
11
Zimmer Biomet
ZBH
$17.8B
$121M 2.82%
1,400,000
+1,210,000
+637% +$106M
IRON icon
12
Disc Medicine
IRON
$2.71B
$113M 2.65%
1,550,000
+850,000
+121% +$58.4M
GLUE icon
13
Monte Rosa Therapeutics
GLUE
$1.21B
$111M 2.6%
4,600,000
+996,535
+28% +$18.8M
PODD icon
14
Insulet
PODD
$9.2B
$102M 2.38%
670,000
+619,399
+1,224% +$103M
ASND icon
15
Ascendis Pharma A/S
ASND
$17.4B
$100M 2.34%
375,000
– –
AZN icon
16
AstraZeneca
AZN
$248B
$85.3M 1.99%
450,000
+350,000
+350% +$65.8M
SNY icon
17
Sanofi
SNY
$102B
$85.3M 1.99%
2,000,000
+600,000
+43% +$26.8M
RVMD icon
18
Revolution Medicines
RVMD
$43.7B
$84.3M 1.97%
450,000
-1,925,000
-81% -$281M
BCRX icon
19
BioCryst Pharmaceuticals
BCRX
$2.09B
$83M 1.94%
8,300,000
+1,275,000
+18% +$11.5M
DYN icon
20
Dyne Therapeutics
DYN
$3.37B
$75M 1.75%
3,375,000
-625,000
-16% -$11.6M
NKTR icon
21
Nektar Therapeutics
NKTR
$2.37B
$69.8M 1.63%
1,000,000
+715,000
+251% +$52.3M
GMED icon
22
Globus Medical
GMED
$9.93B
$67.2M 1.57%
850,000
+239,480
+39% +$20.4M
TARS icon
23
Tarsus Pharmaceuticals
TARS
$3.49B
$66.1M 1.54%
1,050,000
+850,000
+425% +$54.3M
IMTX icon
24
Immatics
IMTX
$1.34B
$62.6M 1.46%
6,175,000
– –
TRVI icon
25
Trevi Therapeutics
TRVI
$2.29B
$57.8M 1.35%
3,100,000
+933,496
+43% +$13.6M
1
2 3 4

Similar funds

DILIC
Dai-ichi Life Insurance Company Tokyo, Japan $4.28B AUM 43.07% 1-Year Est. Return
HCC
Hill City Capital Boston, Massachusetts $4.28B AUM 80.76% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $4.29B AUM 4.26% 1-Year Est. Return
MA
Marshfield Associates Washington, District of Columbia $4.26B AUM 12.94% 1-Year Est. Return
GHC
Great Hill Capital New York $4.29B AUM 18.17% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

Vestal Point Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Vestal Point Capital held 99 positions worth $4.28B, up 20% from $3.58B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Vestal Point Capital's Q2 2026 filing shows 9 new, 31 increased, 22 reduced and 31 closed positions. Its largest new stake was Abbott: 1,400,000 shares worth $127M. The largest sale was Revolution Medicines, an estimated $281M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Vestal Point Capital's largest Q2 2026 buy was Abbott: 1,400,000 shares worth $127M.
  • Vestal Point Capital added most to United Therapeutics in Q2 2026, an estimated $203M increase.
  • Vestal Point Capital's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $281M.
  • Vestal Point Capital fully exited Apogee Therapeutics in Q2 2026, selling an estimated $92.6M.
  • Vestal Point Capital's ten largest holdings make up 50% of its $4.28B portfolio in Q2 2026.
  • Vestal Point Capital opened 9 new positions and closed 31 in Q2 2026.
  • Vestal Point Capital's portfolio value rose 20% quarter-over-quarter to $4.28B.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.